SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTern Regulatory News (TERN)

Share Price Information for Tern (TERN)

Share Price is delayed by 15 minutes
Get Live Data
1.20    0.00 (0.00%)
Bid:
1.10
Ask:
1.30
Spread: 0.20 (18.182%)
Market Cap: £10.27m
TERN Live PriceLast checked at - London Stock Exchange

Intraday Tern Share Chart

Further FundamentalVR contract win

2 Dec 2020 07:00

RNS Number : 1891H
Tern PLC
02 December 2020
 

REACH

 

2 December 2020

 

Tern Plc

("Tern" or the "Company")

 

Further FundamentalVR contract win

 

Tern Plc (AIM:TERN), the investment company specialising in the Internet of Things ("IoT"), is pleased to announce that its portfolio company, FVRVS Limited ("FundamentalVR"), has secured a further £0.4 million contract with an existing client, one of the world's leading pharmaceutical companies (the "Client"), to support training and adoption of its Ocular Gene Therapy product.

 

The contract covers ongoing repeat licences and support to continue the global rollout of the Client's virtual reality training solution, built by FundamentalVR. The rollout of the virtual reality simulation is intended to deliver the Client's ambitions to accelerate the safe and compliant use of its products. The Client will harness FundamentalVR's unique HapticVR technology, combining real life medical devices with virtual "digital twins" of those devices, allowing surgeons to interact with virtual patient tissue.

 

FundamentalVR's award winning platform combines immersive virtual reality with cutting-edge haptics (the sense of touch, weight, pressure and resistance) to create low-cost, measurable and scalable simulation experiences to accelerate medical product and procedural safe, compliant adoption. The platform allows its users to participate in safe, remote and multiuser skills training which is becoming increasingly important in light of Covid-19.

 

Commenting Al Sisto, CEO of Tern, said: "We are delighted that FundamentalVR has secured its third significant contract in the space of a week. FundamentalVR's virtual reality training solutions are gaining real traction in the market and are addressing a need that has been brought into strong focus by the Covid-19 pandemic.

 

"Our other portfolio companies are also making good progress and we look forward to announcing further significant developments in due course."

 

Enquiries

 

Tern Plc

Al Sisto (CEO)

Sarah Payne (CFO)

via IFC Advisory

 

Allenby Capital Limited

(Nominated Adviser and Broker)

David Worlidge / Alex Brearley (Corporate Finance)

Guy McDougall (Equity Sales)

 

Tel: 0203 328 5656

 

IFC Advisory

(Financial PR and IR)

Tim Metcalfe

Graham Herring

Florence Chandler

 

Tel: 0203 934 6630

tern@investor-focus.co.uk

 

About FundamentalVR

 

FundamentalVR delivers VR haptic 'flight simulators' for surgery creating a safe, measurable and repeatable space to refine skills. FundamentalVR's goal is to transform the way surgeons prepare, practice, and refine their skills. It has built an immersive, surgical simulation application platform, Fundamental Surgery, to provide medical professionals with the opportunity to rehearse, practice, and test themselves within a safe, controllable space that is as close to real-life as possible.

 

Tern's shareholding in FundamentalVR is 26.9% and as at 30 June 2020 this holding had a book valuation of £3.0 million.

 

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAKKDBBOBDDPBK
Date   Source Headline
23rd May 20237:00 amRNSNotice of Final Results & Investor Q&A Session
25th Apr 20237:00 amRNSKonektio Fundraise
18th Apr 20237:00 amRNSPortfolio Update and Investor Presentation
31st Mar 20239:00 amRNSWyld Networks Q4 2022 Interim Report
13th Mar 20237:45 amRNSWyld Networks SEK 9.2 million Purchase Order
13th Mar 20237:00 amRNSStatement regarding Silicon Valley Bank
10th Feb 20234:35 pmRNSPrice Monitoring Extension
8th Feb 20238:49 amRNSInvestor webinar recording
7th Feb 20237:00 amRNSOnline Investor Presentation and Q&A Session
2nd Feb 202311:08 amRNSProposed Wyld Networks Directorate Change
25th Jan 20237:00 amRNSPortfolio Update & Investor Presentation
12th Jan 20237:30 amRNSWyld Networks SEK 12.6 million Purchase Order
30th Dec 20221:00 pmRNSTotal Voting Rights
22nd Dec 20222:31 pmRNSFurther re. Wyld Networks Warrant Exercise
22nd Dec 20227:00 amRNSKonektio Secondment
21st Dec 20223:14 pmRNSHolding(s) in Company
13th Dec 20227:00 amRNSWyld Networks Warrant Exercise
8th Dec 20227:45 amRNSLaunch of Wyld Networks Satellite IoT Network
8th Dec 20227:00 amRNSSubscription to raise £1.5 million
2nd Dec 20227:00 amRNSDevice Authority Contract Wins
30th Nov 20227:45 amRNSWyld Networks Q3 2022 Results
7th Nov 20227:00 amRNSWyld Networks Fundraise
31st Oct 20225:00 pmRNSTotal Voting Rights
28th Oct 20227:45 amRNSDevice Authority convertible loan note funding
26th Oct 20227:00 amRNSHolding(s) in Company
25th Oct 20224:41 pmRNSSecond Price Monitoring Extn
25th Oct 20224:36 pmRNSPrice Monitoring Extension
17th Oct 20227:00 amRNSHoling(s) in Company
17th Oct 20227:00 amRNSHolding(s) in Company
12th Oct 20228:05 amRNSDirector Shareholdings and TVR
6th Oct 20227:00 amRNSResult of Fundraise
5th Oct 20224:37 pmRNSRetail Offer by PrimaryBid
5th Oct 20224:36 pmRNSEquity Fundraise of up to £2 million
28th Sep 20227:00 amRNSInvestor webinar recording
23rd Sep 20227:00 amRNSInterim Results
23rd Sep 20227:00 amRNSInterim Results
31st Aug 20225:00 pmRNSTotal Voting Rights
24th Aug 20227:00 amRNSChief Executive Officer Subscription
18th Aug 20227:00 amRNSFurther re. FundamentalVR Fund Raise
11th Aug 20222:05 pmRNSFundamentalVR Fund Raise
28th Jul 20222:43 pmRNSDirector Share Purchase
21st Jul 20221:33 pmRNSStrategic Update
21st Jul 20221:31 pmRNSUpdate re Tern General Meeting & Lapsing of Scheme
21st Jul 20221:30 pmRNSResults of Court Meeting & GM & Lapsing of Scheme
21st Jul 202212:54 pmRNSForm 8.3 - Tern PLC
20th Jul 20221:50 pmRNSForm 8.3 - Tern PLC
19th Jul 20224:53 pmRNSForm 8.3 - Tern PLC
15th Jul 20223:00 pmRNSDisclosure under Rule 20.3(b): DirectorsTalk video
11th Jul 20222:00 pmRNSDisclosure under Rule 20.1
28th Jun 20225:00 pmRNSNotice of Tern General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.